NorthKorea
Top News
Hanmi Pharmaceutical to Present Phase 2 Clinical Results for Congenital Hyperinsulinism...
Hanmi Pharmaceutical will present Phase 2 data on its investigational treatment efpeglenatide (HM15136) for congenital hyperinsulinism at the 64th European Society for Paediatric Endocrinology meeting in France.
- Our Sponsors Ad -